The Observational Medical Outcomes Partnership (OMOP) common data model (CDM) supports large-scale research by enabling distributed network analyses. However, the breadth of its adoption in cancer research is not well understood. We conducted a scoping review to describe the adoption of the OMOP CDM in cancer research. A total of 49 unique articles were included in the review, with 30 on the data analysis theme, and 20 on the infrastructure theme. This review highlighted that while the OMOP CDM ecosystem has enabled successful data support for cancer research, particularly for collaborative studies, ongoing model development and iterative improvement remain needed to fulfill additional research data needs. Expanding disease sites, specifically for rare cancers, integrating more diverse types of data sources, improving data quality, adopting advanced analytics methodology, and increasing multisite evaluations serve as important opportunities to facilitate secondary usage of observational data in future cancer research.